TxCell's Manufacturing Facility Approved for Cell-Therapy Production - - BioPharm International

ADVERTISEMENT

TxCell's Manufacturing Facility Approved for Cell-Therapy Production


TxCell, a biotechnology company specializing in the development of personalized cell-based immunotherapies, has received manufacturing accreditation status of its cell-therapy production site in Besancon, France, from the French National Agency for Drug Safety (ANSM). TxCell develops antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases.

The company’s manufacturing facility, located at the French National Blood Center of Bourgogne Franche-Comte region, is now authorized to produce biological investigational medicinal products in accordance with the European Union Directives 2001/83/EC and 2001/20/EC, as required for the manufacturing of Advance Therapy Medicinal Product (ATMP). The company will now be able to manufacture batches of Ovasave (its lead autologous Ag-Treg cell-based immunotherapy) for clinical testing in patients with Crohn’s disease. The 440 m2 facility includes 120 m2 of cleanroom suites of which 80 m2 are Grade B suits under GMP EU classification. TxCell has a manufacturing capacity of more than 20 cell therapy batches in parallel.

“This manufacturing accreditation from ANSM is a key milestone in the planned future development and growth of TxCell,” said Damian Marron, CEO of TxCell, in a press statement. “This is essential for scaling up manufacturing of TxCell’s lead product Ovasave for our forthcoming Phase IIb in refractory Crohn’s Disease. This in turn allows us to accelerate the development of all our innovative, personalized cell-based immunotherapies. These therapies target niche and orphan indications for which there are few or no treatment options and a high unmet medical need.”

Source: TxCell

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines

Click here